BETHESDA, Md., Oct. 20, 2014 /PRNewswire/ -- Pinney Associates, Inc. celebrates 20 years of helping consumer healthcare and pharmaceutical companies to make science-based decisions for the betterment of public health. Founded in 1994 by John Pinney, today PinneyAssociates is a consulting leader in prescription to over-the-counter (Rx-to-OTC) switch, the support of marketed consumer healthcare products, pharmaceutical risk management, abuse potential assessment, and abuse-deterrent drug products.
"I am proud of our many successes and our ongoing commitment to furthering public health," said John M. Pinney, Founder and Chief Executive Officer of PinneyAssociates. "After 20 years, we continue to bring the experience and expertise of our diverse group of scientists and health policy experts to helping our consumer healthcare and pharmaceutical clients develop and implement science-based solutions to complex problems."
PinneyAssociates serves the consumer healthcare and pharmaceutical industries, including innovator research and discovery companies, and manufacturers and distributors of branded and generic drug products.
Throughout the years, PinneyAssociates and its leadership have made significant contributions to public health and health policy. We continue to be a leader in:
- Promoting the value of Rx-to-OTC switches, direct-to-OTC approvals, and approved OTC products. Led by Saul Shiffman, PhD, and Lucy Owen our experts provide comprehensive support throughout the product lifecycle including counsel on labeling, consumer behavior research, and post-marketing support.
- Promoting a deeper understanding of the complexities of pharmaceutical risk management for psychoactive medicines. Under the guidance of Sidney Schnoll, MD, PhD, we provide advice on the most appropriate risk management path to enhance product safety and marketability through premarketing risk assessment of the scientific and policy environment. This includes support implementation and evaluation of risk management programs and Risk Evaluation and Mitigation Strategies (REMS) for individual compounds and formulations, and class-wide REMS.
- Advancing the science of in vitro assessment of abuse-deterrent drugs and formulations ("tamper testing") and drug abuse potential assessment. Under the leadership of Edward Cone, PhD, and Jack Henningfield, PhD, our experts provide strategic advice and other support related to assessment of tamper-deterrent medications and abuse liability assessments within the context of scheduling and labeling regulations.
- Expansion of tobacco dependence treatment availability, raising awareness of the challenges in promoting "reduced risk" tobacco and nicotine products, and promoting thoughtful and balanced approaches to tobacco harm minimization. Led by Joe Gitchell and Saul Shiffman, PhD, we address tobacco and public health issues with the federal government, academia, health voluntary organizations, and as consultants to the private sector with the goal of minimizing, and eventually eliminating, the harm caused by the use of tobacco products.
In 1994, the company was launched with five employees. Today, our clients know they can rely on our 25 scientists, policy experts, researchers, analysts, and support staff.
"After 20 years, our clients continue to rely on the high-quality client service we provide and the strategic solutions we develop to successfully address regulatory, scientific, and health policy challenges," said Joe G. Gitchell, President of PinneyAssociates.
PinneyAssociates' senior leadership includes internationally respected leaders at the intersection of public health, behavioral science, and the development and marketing of medicines. We help our clients to manage issues and enhance the scientific and policy environments to gain regulatory approval of, and maximize acceptance of, consumer healthcare and pharmaceutical products.
For more information, please visit www.pinneyassociates.com or call +1 301-718-8440.